Bristol Myers Squibb (BMY) Accumulated Expenses (2009 - 2019)

Bristol Myers Squibb (BMY) has reported Accumulated Expenses for 11 consecutive years, with $5.9 billion the latest figure, recorded in Q1 2019.

• On a quarterly basis, Accumulated Expenses rose 5.3% year-over-year to $5.9 billion in Q1 2019; TTM through Mar 2019 was $5.9 billion, a 5.3% increase from a year earlier, with the FY2018 full-year figure at $6.5 billion, up 7.9% from the prior year.
• Accumulated Expenses was $5.9 billion for Q1 2019 at Bristol Myers Squibb, down from $6.5 billion in the prior quarter.
• Over five years, Accumulated Expenses peaked at $6.5 billion in Q4 2018 and troughed at $1.8 billion in Q1 2015.
• A 5-year average of $4.8 billion and a median of $5.1 billion in 2017 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses decreased 10.32% in 2015 and jumped 140.7% in 2016, its largest moves.
• Over 5 years, Accumulated Expenses stood at $4.7 billion in 2015, then advanced by 11.25% to $5.3 billion in 2016, then advanced by 14.1% to $6.0 billion in 2017, then rose by 7.9% to $6.5 billion in 2018, then declined by 9.75% to $5.9 billion in 2019.
• The last three Accumulated Expenses figures came in at $5.9 billion (Q1 2019), $6.5 billion (Q4 2018), and $5.9 billion (Q3 2018), per Business Quant data.